TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Acquired by Barclays PLC

Barclays PLC increased its position in shares of TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 83.9% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 347,057 shares of the biopharmaceutical company's stock after purchasing an additional 158,323 shares during the period. Barclays PLC owned 0.22% of TG Therapeutics worth $8,117,000 at the end of the most recent quarter.

Other large investors have also recently bought and sold shares of the company. NBC Securities Inc. boosted its position in shares of TG Therapeutics by 58.9% during the 3rd quarter. NBC Securities Inc. now owns 1,309 shares of the biopharmaceutical company's stock worth $30,000 after acquiring an additional 485 shares in the last quarter. Ashton Thomas Private Wealth LLC purchased a new stake in TG Therapeutics during the second quarter worth approximately $35,000. Blue Trust Inc. boosted its holdings in TG Therapeutics by 127.3% in the third quarter. Blue Trust Inc. now owns 1,516 shares of the biopharmaceutical company's stock valued at $35,000 after purchasing an additional 849 shares in the last quarter. ORG Wealth Partners LLC purchased a new position in TG Therapeutics in the third quarter valued at approximately $53,000. Finally, Values First Advisors Inc. acquired a new stake in TG Therapeutics during the third quarter worth approximately $58,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

TG Therapeutics Price Performance

Shares of TG Therapeutics stock traded down $2.50 during trading on Wednesday, reaching $31.07. The company's stock had a trading volume of 2,469,448 shares, compared to its average volume of 3,596,145. The business has a 50 day moving average price of $29.06 and a 200-day moving average price of $23.69. TG Therapeutics, Inc. has a 12-month low of $12.84 and a 12-month high of $36.84. The company has a market capitalization of $4.84 billion, a P/E ratio of -310.67 and a beta of 2.25. The company has a quick ratio of 3.91, a current ratio of 4.59 and a debt-to-equity ratio of 1.27.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last released its earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 EPS for the quarter, missing analysts' consensus estimates of $0.03 by ($0.01). The business had revenue of $83.90 million during the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. TG Therapeutics's revenue was down 49.4% compared to the same quarter last year. During the same period last year, the business posted $0.73 EPS. As a group, sell-side analysts anticipate that TG Therapeutics, Inc. will post 0.17 EPS for the current year.

Insiders Place Their Bets

In related news, Director Sagar Lonial sold 5,000 shares of the company's stock in a transaction on Monday, November 11th. The shares were sold at an average price of $30.44, for a total transaction of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares of the company's stock, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 10.50% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have recently issued reports on TGTX. TD Cowen assumed coverage on shares of TG Therapeutics in a report on Tuesday, October 29th. They issued a "buy" rating and a $50.00 target price for the company. The Goldman Sachs Group raised their price objective on TG Therapeutics from $20.00 to $22.00 and gave the stock a "neutral" rating in a report on Tuesday, November 5th. HC Wainwright upped their target price on TG Therapeutics from $49.00 to $55.00 and gave the company a "buy" rating in a research report on Tuesday, November 5th. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday. Finally, JPMorgan Chase & Co. raised their target price on shares of TG Therapeutics from $30.00 to $43.00 and gave the stock an "overweight" rating in a research report on Monday, November 25th. Two equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $40.67.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.